A New Start II, LLC

A New Start II, LLC was paid $22.10M by Medicaid between Jan 2018 and Dec 2024, across 35 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 25% of everything it billed.

Compared with peers

Next to other Counselor providers in Kentucky

Rank by total paid#2 of 55

Median peer was paid$202K

This provider vs. median109×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	59,056	$872K
2019	82,630	$1.40M
2020	103,422	$4.62M
2021	86,923	$4.61M
2022	93,416	$5.21M
2023	66,219	$3.60M
2024incomplete	35,898	$1.79M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	25%	38,147	29,796	$5.62M
T2023	Targeted case management; per month	21%	12,326	11,129	$4.66M
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	18%	111,534	58,257	$3.87M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	14%	76,381	43,055	$3.06M
H0038	Self-help/peer services, per 15 minutes	6.5%	113,461	35,353	$1.45M
H2027	Psychoeducational service, per 15 minutes	4.4%	20,568	17,393	$976K
90832	Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient	3.9%	29,688	21,584	$866K
90853	Group psychotherapy (other than of a multiple-family group)	1.2%	30,949	16,947	$261K
80305		1.1%	44,862	17,262	$241K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,328	2,889	$217K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	<1%	6,089	3,593	$210K
90791	Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation	<1%	1,642	1,359	$95K

23 more codes

99204	Doctor's office visit, new patient (more involved)	<1%	1,833	$92K
90837	Psychotherapy session, about an hour	<1%	3,096	$84K
T1007	Alcohol and/or substance abuse services, treatment plan development and/or modification	<1%	1,099	$68K
99406		<1%	12,167	$66K
81025		<1%	11,047	$56K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	531	$49K
99442		<1%	1,191	$31K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	1,157	$24K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	1,157	$24K
87563		<1%	1,181	$24K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	1,181	$24K
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	<1%	222	$7K
99203	Doctor's office visit, new patient (routine)	<1%	129	$6K
99205	Prolong outpt/office vis	<1%	170	$5K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	274	$4K
80053	Comprehensive metabolic panel	<1%	580	$4K
99441		<1%	192	$3K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	516	$2K
86803		<1%	274	$2K
86705		<1%	274	$2K
87340		<1%	269	$2K
99443		<1%	27	$1K
H0027	Alcohol and/or drug prevention environmental service (broad range of external activities geared toward modifying systems in order to mainstream prevention through policy and law)	0%	22	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVINCENT, WILLIAM (ADMINISTRATOR)